Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

This Week In Biotech (6/12/16)

|Includes: EPZM, iShares Nasdaq Biotechnology ETF (IBB), XBI
This Article Originally Appeared On: Http://AgeOfBiotech.comLast week:

This past week was an interesting one in the biotechnology industry. #ASCO16 wrapped up with a speech from Vice President Joe Biden. Mid week, Sarepta Therapeutics (NASDAQ:SRPT) announced an offering of common stock in order to raise money for operations. The positive reaction to the offering may have surprised some, but not us. #EHA16 started, and while it wasn't as active on Twitter as we would have liked, although we did get some data fom 3 companies who presented there today. Today Uniqure, Alnylam and Agios all presented data at #EHA16. We wrote about the Uniqure data here. Lastly, there was one more piece of news that broke this past week that we found interesting, but didn't get the opportunity to write about. You can read how Canadian scientists reversed severe M.S. using stem cells here.

This Week(June 12th):

Looking forward, excluding any unexpected events, this week is looking a bit more quiet than last. There are no scheduled PDUFA dates, and no big healthcare conferences scheduled until Saturday the 18th. Next week the ASH Lymphoma conference and the International Society of Stem Cell Research (#ISSCR) annual meeting should provide us with some data & interesting news.

On Saturday June 18th: Epizyme (NASDAQ:EPZM) will be presenting a Phase II update of Tazemetostat for Relapsed or Refractory Non Hodgkins Lymphoma at the ASH Meeting on Lymphoma Biology. That conference begins on the 18th and rolls into early next week.

Check back to AgeOfBiotech during the week for news on any unexpected events in the industry !

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.